Cheng Sohanya Roshan 4
4 · Karyopharm Therapeutics Inc. · Filed Sep 1, 2022
Insider Transaction Report
Form 4
Cheng Sohanya Roshan
EVP & Chief Commercial Officer
Transactions
- Award
Common Stock
2022-08-31+30,000→ 119,949 total - Award
Stock Option (right to buy)
2022-08-31+45,000→ 45,000 totalExercise: $5.06Exp: 2032-08-30→ Common Stock (45,000 underlying)
Footnotes (2)
- [F1]Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest as to 50% of the shares on August 31, 2023, with the remaining 50% vesting on August 31, 2024.
- [F2]This option was granted on August 31, 2022 pursuant to the Plan. The shares underlying this option vest as to 50% of the shares on August 31, 2023, with the remaining 50% vesting on August 31, 2024.